Type II calcimimetics and polycystic kidney disease: Unanswered questions

Journal of the American Society of Nephrology

Volumn 20, Issue 7, 2009, Pages 1421-1425

  Torres, Vicente E ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ACYLAMINO) 3 THIOPHENECARBOXYLATE DERIVATIVE; CALCIMIMETIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; FIBROCYSTIN; MOZAVAPTAN; PARATHYROID HORMONE; POLYCYSTIN 1; POLYCYSTIN 2; PROSTAGLANDIN E2; R 568; SOMATOSTATIN; THIOPHENE DERIVATIVE; TOLVAPTAN; TRIPTOLIDE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL CONTACT; CELL POLARITY; CELL PROLIFERATION; DRUG BINDING; DRUG EFFECT; EDITORIAL; GENE MUTATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

EID: 67649690151     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009050501     Document Type: Editorial

References (64)

1. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: The last three years. Kidney Int May 20, 2009 [epub ahead of print]
2. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007 (Pubitemid 46552051)
3. Grantham JJ: Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease: Understanding polycystic kidney disease - A systems biology approach. Kidney Int 64: 1157-1162, 2003 (Pubitemid 37153779)
4. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 40419-40430, 2004 (Pubitemid 39287631)
5. Kottgen M: TRPP2 and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 1772: 836-850, 2007 (Pubitemid 47179879)
6. Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB: Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 12: R378-R380, 2002 (Pubitemid 34689219)
7. Yoder BK, Hou X, Guay-Woodford LM: The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13: 2508-2516, 2002
8. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J: Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33: 129-137, 2003 (Pubitemid 36177063)
9. Ward CJ, Yuan D, Masyuk TV, Wang X, Punyashthiti R, Whelan S, Bacallao R, Torra R, LaRusso NF, Torres VE, Harris PC: Cellular and subcellular localization of the ARPKD protein: Fibrocystin is expressed on primary cilia. Hum Mol Genet 12: 2703-2710, 2003 (Pubitemid 37304692)
10. Wang S, Zhang J, Nauli SM, Li X, Starremans PG, Luo Y, Roberts KA, Zhou J: Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 27: 3241-3252, 2007 (Pubitemid 46581334)
11. Bai CX, Giamarchi A, Rodat-Despoix L, Padilla F, Downs T, Tsiokas L, Delmas P: Formation of a new receptor-operated channel by heteromeric assembly of TRPP2 and TRPC1 subunits. EMBO Rep 9: 472-479, 2008 (Pubitemid 351627286)
12. Du J, Ding M, Sours-Brothers S, Graham S, Ma R: Mediation of angiotensin II-induced Ca2+ signaling by polycystin 2 in glomerular mesangial cells. Am J Physiol Renal Physiol 294: F909-F918, 2008
13. Kottgen M, Buchholz B, Garcia-Gonzalez MA, Kotsis F, Fu X, Doerken M, Boehlke C, Steffl D, Tauber R, Wegierski T, Nitschke R, Suzuki M, Kramer-Zucker A, Germino GG, Watnick T, Prenen J, Nilius B, Kuehn EW, Walz G: TRPP2 and TRPV4 form a polymodal sensory channel complex. J Cell Biol 182: 437-447, 2008
14. Tsiokas L, Arnould T, Shu C, Kim E, Walz G, Sukhatme VP: Specific association of the gene product of PKD2 with the TRPC1 channel. Proc Natl Acad Sci U S A 96: 3934-3939, 1999 (Pubitemid 29169014)
15. Anyatonwu GI, Estrada M, Tian X, Somlo S, Ehrlich BE: Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc Natl Acad Sci U S A 104: 6454-6459, 2007 (Pubitemid 47186115)
16. Li Y, Wright JM, Qian F, Germino GG, Guggino WB: Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J Biol Chem 280: 41298-41306, 2005 (Pubitemid 41832186)
17. Banizs B, Komlosi P, Bevensee MO, Schwiebert EM, Bell PD, Yoder BK: Altered pHi regulation and Na+/HCO3- transporter activity in choroid plexus of cilia-defective Tg737orpk mutant mouse. Am J Physiol Cell Physiol 292: C1409-C1416, 2007
18. Gattone VH, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003 (Pubitemid 37279858)
19. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF: Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132: 1104-1116, 2007 (Pubitemid 46440866)
20. Qian Q, Hunter LW, Li M, Marin-Padilla M, Prakash YS, Harris PC, Somlo S, Torres VE, Sieck GC: Pkd2 haploinsufficiency alters intracellular calcium in vascular smooth muscle cells. Hum Mol Genet 12: 1875-1880, 2003
21. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O: Development of polycystic kidney disease in juvenile cystic kidney mice: Insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17: 2821-2831, 2006 (Pubitemid 44484672)
22. Starremans PG, Li X, Finnerty PE, Guo L, Takakura A, Neilson EG, Zhou J: A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5′ end of Pkd1. Kidney Int 73: 1394-1405, 2008 (Pubitemid 351770482)
23. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004 (Pubitemid 38508512)
24. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham J: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997 (Pubitemid 27465366)
25. Hanaoka K, Guggino W: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11: 1179-1187, 2000 (Pubitemid 30416213)
26. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ: Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003 (Pubitemid 36605809)
27. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006
28. Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP: Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 73: 269-277, 2008
29. Leuenroth SJ, Bencivenga N, Igarashi P, Somlo S, Crews CM: Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 19: 1659-1662, 2008
30. Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, Crews CM: Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A 104: 4389-4394, 2007 (Pubitemid 47186236)
31. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006 (Pubitemid 44141912)
32. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005 (Pubitemid 41710293)
33. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in the PCK rat. J Am Soc Nephrol 19: 102-108, 2008
34. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM, Grantham JJ: Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964-973, 2004 (Pubitemid 39120999)
35. Elberg G, Elberg D, Lewis TV, Guruswamy S, Chen L, Logan CJ, Chan MD, Turman MA: EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells. Am J Physiol Renal Physiol 293: F1622-F1632, 2007
36. Sankaran D, Bankovic-Calic N, Ogborn MR, Crow G, Aukema HM: Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 293: F821-F830, 2007 (Pubitemid 47403352)
37. Tradtrantip L, Yangthara B, Padmawar P, Morrison C, Verkman AS: ThiopheneCaSRboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion. Mol Pharmacol 75: 134-142, 2009
38. Brown EM: Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3: 122-133, 2007 (Pubitemid 46146965)
39. Brown EM, MacLeod RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239-297, 2001 (Pubitemid 32096177)
40. Huang C, Miller RT: Regulation of renal ion transport by the calciumsensing receptor: An update. Curr Opin Nephrol Hypertens 16: 437-443, 2007 (Pubitemid 47254694)
41. Abdullah HI, Pedraza PL, McGiff JC, Ferreri NR: Calcium-sensing receptor signaling pathways in medullary thick ascending limb cells mediate COX-2-derived PGE2 production: functional significance. Am J Physiol Renal Physiol 295: F1082-F1089, 2008
42. Wang W, Lu M, Balazy M, Hebert SC: Phospholipase A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL. Am J Physiol 273: F421-F429, 1997
43. Wang WH, Lu M, Hebert SC: Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 271: C103-C111, 1996 (Pubitemid 26298781)
44. Park F, Sweeney WE, Jia G, Roman RJ, Avner ED: 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease. J Am Soc Nephrol 19: 1929-1939, 2008
45. Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH: Expression and function of the calcium-sensing receptor in juxtaglomerular cells. Hypertension 50: 737-743, 2007 (Pubitemid 47442739)
46. Sands JM, Flores FX, Kato A, Baum MA, Brown EM, Ward DT, Hebert SC, Harris HW: Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. Am J Physiol 274: F978-F985, 1998 (Pubitemid 28255877)
47. Lee M, Partridge NC: Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens April 22, 2009 [epub ahead of print]
48. Bajwa A, Forster MN, Maiti A, Woolbright BL, Beckman MJ: Specific regulation of CYP27B1 and VDR in proximal versus distal renal cells. Arch Biochem Biophys 477: 33-42, 2008
49. Gattone VH II, Chen NX, Sinders RM, Seifert MF, Duan D, Martin D, Henley C, Moe SM: Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol 20: 1527-1532, 2009
50. Wang X, Harris PC, Somlo S, Batlle D, Torres VE: Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transplant 24: 526-534, 2009
51. Cowley B Jr, Gudapaty S, Kraybill A, Barash B, Harding M, Calvet J, Gattone VD: Autosomal dominant polycystic kidney disease in the rat. Kidney Int 43: 522-534, 1993 (Pubitemid 23071934)
52. Schäfer K, Gretz N, Bader M, Oberbäumer I, Eckardt K-U, Kriz W, Bachmann S: Characterisation of the Han-SPRD rat model for hereditary polycystic kidney disease. Kidney Int 46: 134-152, 1994
53. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
54. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE: The pck rat: A new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59: 126-136, 2001 (Pubitemid 32055221)
55. Torres VE: Vasopressin antagonists in polycystic kidney disease. Kidney Int 68: 2405-2418, 2005 (Pubitemid 43117830)
56. Wu G, D'Agati V, Cai Y, Markowitz G, Park J, Reynolds D, Maeda Y, Le T, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S: Somatic inactivation of PKD2 results in polycystic kidney disease. Cell 93: 177-188, 1998 (Pubitemid 28180852)
57. Costa MZ, Bacchi CE, Franco M: Histogenesis of the acquired cystic kidney disease: An immunohistochemical study. Appl Immunohistochem Mol Morphol 14: 348-352, 2006 (Pubitemid 44319063)
58. Ishikawa I, Horiguchi T, Shikura N: Lectin peroxidase conjugate reactivity in acquired cystic disease of the kidney. Nephron 51: 211-214, 1989 (Pubitemid 19037694)
59. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and CaSRdiovascular risk factors. J Am Soc Nephrol 14: 959-967, 2003 (Pubitemid 36359277)
60. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML: Calcimimetic R-568 or calcitriol: Equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294: F748-F257, 2008
61. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML: Interstitial fibrosis and microvascular disease of the heart in uremia: Amelioration by a calcimimetic. Lab Invest 89: 520-530, 2009
62. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCaSRy LC, Pichette V: Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58-67, 2005 (Pubitemid 40852012)
63. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA: A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53: 197-207, 2009
64. Kalantar-Zadeh K, Kovesdy CP: Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. Am J Kidney Dis 53: 183-188, 2009